Jatenzo

Jatenzo · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 6, 2027

183 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (64)

Apr 28, 2041formulationUS 11464735
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Mar 29, 2041formulationUS 12403146
Oct 16, 2040formulationUS 12011503
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Apr 12, 2039method-of-use (U-1103)US 11564933
Feb 21, 2039method-of-use (U-4194)US 12310978
Nov 28, 2037method-of-use (U-1500)US 11559530
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 11617758
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Mar 15, 2033formulationUS 12357643
Dec 31, 2030formulationUS 105760894.5y
Dec 31, 2030formulationUS 105760894.5y
Dec 31, 2030formulationUS 105760894.5y
Dec 31, 2030formulationUS 105760904.5y
Dec 31, 2030formulationUS 105760904.5y
Dec 31, 2030formulationUS 105760904.5y
Dec 31, 2030formulationUS 115901464.5y
Dec 31, 2030formulationUS 115901464.5y
Dec 31, 2030formulationUS 115901464.5y
Dec 20, 2030formulationUS 84923694.5y
Dec 20, 2030formulationUS 84923694.5y
Dec 20, 2030formulationUS 84923694.5y
Nov 30, 2030method-of-use (U-1500)US 102264734.4y
Nov 30, 2030method-of-use (U-1500)US 107167944.4y
Nov 30, 2030method-of-use (U-1500)US 113115554.4y
Nov 30, 2030method-of-use (U-1500)US 113642494.4y
Nov 30, 2030method-of-use (U-1500)US 114330834.4y
Nov 30, 2030method-of-use (U-1500)US 99435274.4y
Nov 30, 2030method-of-use (U-1500)US 99499854.4y
Apr 12, 2030method-of-use (U-2506)US 105432193.8y
Apr 12, 2030method-of-use (U-2506)US 105432193.8y
Apr 12, 2030method-of-use (U-2506)US 105432193.8y
Apr 12, 2030compositionUS 106176963.8y
Apr 12, 2030compositionUS 106176963.8y
Apr 12, 2030compositionUS 106176963.8y
Apr 12, 2030method-of-use (U-2506)US 111794033.8y
Apr 12, 2030method-of-use (U-2506)US 111794033.8y
Apr 12, 2030method-of-use (U-2506)US 111794033.8y
Apr 12, 2030method-of-use (U-3420)US 114264163.8y
Apr 12, 2030method-of-use (U-3420)US 114264163.8y
Apr 12, 2030method-of-use (U-3420)US 114264163.8y
Apr 12, 2030formulationUS 87789163.8y
Apr 12, 2030formulationUS 87789163.8y
Apr 12, 2030formulationUS 87789163.8y
Mar 29, 2029formulationUS 82416642.7y
Mar 29, 2029formulationUS 82416642.7y
Mar 29, 2029formulationUS 82416642.7y
Jan 8, 2029formulationUS 113049602.5y
Jan 8, 2029formulationUS 87789222.5y
Jan 8, 2029method-of-use (U-1500)US 88656952.5y
May 8, 2027method-of-use (U-1500)US 8338395305d
Mar 14, 2027formulationUS 7718640250d
Jan 6, 2027method-of-use (U-2506)US 11331325183d
Jan 6, 2027method-of-use (U-2506)US 11331325183d
Jan 6, 2027method-of-use (U-2506)US 11331325183d
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402
Apr 14, 2026compositionUS 11179402

LPCN-1144

targets

all catalysts(0)

News(0)

Report a data issue

Patent cliff

patents (64)

comments(0)

Trials studying LPCN-1144